CGTLive’s Weekly Rewind – August 12, 2022

Article

Review top news and interview highlights from the week ending August 12, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Zolgensma Gene Therapy Linked to 2 Deaths in SMA Patients, Novartis Reports

The 2 deaths, due to acute liver failure, occurred in patients treated in Kazakhstan and Russia.

2. Ide-Cel Shows Benefit in Earlier Use in R/R Multiple Myeloma

A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.

3. UniQure Pauses High Dose of AMT-130 Huntington Disease Gene Therapy for Severe Adverse Events

No such adverse events have occurred in the lower-dose group.

4. First Patient Dosed in Sickle Cell Gene Therapy Clinical Trial From Graphite Bio

Nula-cel is intended to directly correct the mutation that causes sickle cell disease.

5. Frontotemporal Dementia Gene Therapy Trial Initiates Dosing

PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain.

Related Videos
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Mark Walters, MD
© 2024 MJH Life Sciences

All rights reserved.